Table 7 Randomized Controlled Trials of Chemotherapy +/- Glucocorticoids of Breast Cancer in the Adjuvant Setting
From: Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy
Author [reference], Year | Patient Characteristics | Treatment Arms Patient Number (Randomized/Evaluable) | Quality Score | Outcome(s) |
|---|---|---|---|---|
Tormey et al [12], 1990 | Premenopausal, ER+ve 51%, ER-ve 49%, | CMF (222/188) vs. CMFP (220/183) vs. CMFP + tamoxifen 10 mg po twice daily(220/182), all treatments for one year | 2 | median time to relapse: CMF 6.2 months vs. CMFP 6.6 months (p = 0.64), survival: CMF vs. CMFP (p = 0.91) |
Ludwig Breast Cancer Study Group [53, 85], 1985 | pre and peri-menopausal, ER +ve 28%, ER -ve 24% ER unknown 48% | CMF (250/241) vs. CMF + prednisone 7.5 mg daily (255/250), all treatments for one year | 3 | 13 year disease-free survival of 52% vs. 49% (p = 0.39), 13 year overall survival of 65% vs. 59% (p = 0.30) |